It is therefore a main challenge to identify those conditions, and the effects on different cellular phenotypes, under which KLF4 acts as a repressor or as a transcriptional activator in collaboration with different STATs, IRFs, and/or NF-κB, and how this effects vascular function during atherosclerosis. This evidence concerns the gene NFKB1 and atherosclerosis.